Partner Lisa Noller was quoted in an Illinois News Network article, “New Health Care Fraud Unit Targets Violators Scamming the State,” covering why the unit is a step forward for Illinois.
Although Noller said she doesn’t think Illinois is ahead of any other state on this, she did explain that it is a “a positive sign that the U.S. Attorney’s office is dedicating resources to explore the possibility of combating health care fraud.”
Noller added: “The vast majority of providers are absolutely complying with the law. I have full faith in the U.S. Attorney’s office that they’re not going to prosecute or pursue providers who don’t deserve to be pursued.”
Although Noller said she doesn’t think Illinois is ahead of any other state on this, she did explain that it is a “a positive sign that the U.S. Attorney’s office is dedicating resources to explore the possibility of combating health care fraud.”
Noller added: “The vast majority of providers are absolutely complying with the law. I have full faith in the U.S. Attorney’s office that they’re not going to prosecute or pursue providers who don’t deserve to be pursued.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”